The fluoroquinolones

Mayo Clinic Proceedings

Volumn 74, Issue 10, 1999, Pages 1030-1037

  Walker, Randall C ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; FLEROXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; METAL ION; MORPHINE; MOXIFLOXACIN; NALIDIXIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN;

ABDOMINAL INFECTION; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; CONFERENCE PAPER; DRUG ELIMINATION; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIVER CLEARANCE; LIVER TOXICITY; NEUROTOXICITY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; URINARY EXCRETION;

EID: 0032870112     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.10.1030     Document Type: Conference Paper

References (38)

1. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and antitopoisomerase resistance. Clin Infect Dis 1998;27(Suppl 1):S54-S63
2. Gootz TD, Brighty KE. Chemistry and mechanism of action of the quinolone antibacterial. In: Andriole VT, editor. The Quinolones. 2nd ed. San Diego: Academic Press; 1998. pp 29-80
3. Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:2733-2737
4. Köhler T, Pechère JC. Bacterial resistance to quinolones: mechanisms and clinical implications. In: Andriole VT, editor. The Quinolones. 2nd ed. San Diego: Academic Press; 1998. pp 117-142
5. Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 1996;40:2714-2720
6. Deguchl T, Fukuoka A, Yasuda M, Nakano M, Ozekl S, Kanematsu E, et al. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997;41:699-701
7. Andriole VT. The quinolones: prospects. In: Andriole VT, editor. The Quinolones. 2nd ed. San Diego: Academic Press; 1998. pp 417-429
8. Lee BL, Padula AM, Kimbrough RC, Jones SR, Chaisson RE, Mills J, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy [letter]. N EngU Med 1991;325:520-521
9. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996;23(Suppl 1):S19-S24
10. Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS, editors. Quinolone Antimicrobial Agents. 2nd ed. Washington (DC): American Society for Microbiology: 1993. pp 161-193
11. Yew WW, Piddock U, Li MS, Lyon D, Chan CY, Cheng AF. In vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994:34:343-351
12. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am 1995 Sep;9:715-730
13. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [published erratum appears in J Antimicrob Chemother 1998:41:672]. J Antimicrob Chemother 1997:40:639-651
14. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother 1996:40:1048-1049
15. Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997:53:700 725
16. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials [published erratum appears in J Antimicrob Chemother 1994;34:851]. J Antimicrob Chemother 1994: 33:685-706
17. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother 1995:39:2210-2216
18. Lode H. Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998:27:33-39
19. Physicians' Desk Reference. 53rd ed. Montvale (NJ): Medical Economics Company; 1999. pp 643; 1199; 1850; 2185: 2199; 2417: 2603: 2618; 3178
20. Akahane K, Kalo M, Takayama S. Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. Antimicrob Agents Chemother 1993:37:1764-1770
21. Food and Drug Administration. PDA issues public health advisory on liver toxicity associated with the antibiotic Trovan; June 9,1999 [press release]. Available at: www.fda.gov/cder/news/trovan/default.htm
22. Gombert ME, Aulicino TM, duBouchet L, Berkowitz LR. Susceptibility of Nocardia astéroïdes to new quinolones and beta-lactams. Antimicrob Agents Chemother 1987:31:2013-2014
23. Perea EJ, Aznar J, Garcia-Iglesias MC, Pascual A. Comparative invitro activity of sparfloxacin against genital pathogens. J Antimicrob Chemother 1996;37(Suppl A):19-25
24. Chen DK, McGeer A, de Azavedo JC, Low DE (Canadian Bacterial Surveillance Network). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engt J Med 1999;341: 233-239
25. Saiman L, Mehar F, Niu WW. Neu HC, Shaw KJ. Miller G, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-537
26. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-560
27. Gillespie SM, Kennedy N. Fluoropuinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998:2:265-271
28. Iseman MD. Treatment of multidrug-resistant tuberculosis [published erratum appears in W Eng! J Med 1993:329:1435]. N Eng! J Med 1993:329:784-791
29. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997:25:1213-1221
30. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focussing on newer agents. Clin Infect Dis 1999:28:352-364
31. Menschik M, Neumuller J, Steiner CW, Erlacher L, Koller M, Ullrich R, et al. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro. Antimicrob Agents Chemother 1997:41:2562-2565
32. Schaad UB. Use of the quinolones in pediatrics. In: Andriole VT, editor. The Quinolones. 2nd ed. San Diego: Academic Press: 1998. pp 351-367
33. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-1204
34. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relation ship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995:39:520-524
35. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli m fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996:40:503-505
36. Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993:37:1393-1399
37. AcarJF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997:24(Suppl 1):S67-S73
38. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997 Dec:ll:757-765